Year: 2025
Type: article
Abstract: its conserved carbohydrate recognition domain (CRD). The immunomodulatory activity of Gal-1 involves regulation of T cell effector populations, inducing apoptosis of Th1 and Th17 cells, differentiation of tolerogenic dendritic cells and induction of myeloid-derived suppressor cells. To develop a rational galectin-based therapeutic strategy, we evaluated whether Gal-1 retains its function upon multivalent presentation on nanoparticles. Specifically, we report the design strategy, synthesis and characterization of galectin-1-conjugated glucose-stabilized gold nanoparticles, and compare their activities with unconjugated galectin-1. This formulation offers novel opportunities for treating a variety of autoimmune diseases, as well as chronic inflammatory disorders.
Source: RSC Medicinal Chemistry
DOI: 10.1039/d5md00539f
Language: English
Topic: Galectins and Cancer Biology
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Funders: Richard Lounsbery Foundation, Fundación Sales, Max-Planck-Förderstiftung, Deutsche Forschungsgemeinschaft, Consejo Nacional de Investigaciones Científicas y Técnicas, Ministerio de Ciencia, Tecnología e Innovación Productiva, Max-Planck-Gesellschaft, Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación
OpenAlex ID: W4414547266